|
February 3, 2012
|
| 07:39 EDT |  | MDT |
|
|
February 2, 2012
|
| 14:05 EDT |  | MDT |
| theflyonthewall.com: | FDA and industry reach agreement in principle on medical device user fees | | The FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would authorize the FDA to collect $595M in user fees over five years, plus adjustments for inflation. Details of the agreement, such as the fee structure, are expected to be finalized soon. :theflyonthewall.com |
|
| 12:15 EDT | | MDT |
|
| 07:23 EDT | | MDT |
|
|
February 1, 2012
|
| 09:05 EDT | | MDT |
|
| 08:00 EDT | | MDT |
|
|
January 30, 2012
|
| 17:15 EDT | | MDT |
|
| 09:05 EDT | | MDT |
|
|
January 27, 2012
|
| 09:01 EDT | | MDT |
| theflyonthewall.com: | Medtronic launches cardiac surgery products through distribution agreement | | Medtronic announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC – a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery procedures – and has introduced the company’s first two products in the U.S. The first products launched are the Joseph Lamelas Knot Pusher™, which is designed to simplify the delivery and tying of secure suture knots in the heart during MICS procedures, and the Joseph Lamelas Atrial Lift System™, which is used to retract the atrial wall during limited-access cardiac surgical procedures. These products are registered with the FDA and are available for use in the U.S. :theflyonthewall.com |
|
|
January 26, 2012
|
| 08:04 EDT |  | MDT |
| theflyonthewall.com: | NuVasive target raised to $21 from $16 at ThinkEquity | | ThinkEquity raised its target on NuVasive, as the firm sees a much lower chance of a permanent injunction being lodged against the company following a judge's preliminary ruling yesterday. The firm reiterates a Buy rating on the stock. :theflyonthewall.com |
|
| 05:59 EDT | | MDT |
| theflyonthewall.com: | NuVasive shares attractive at current levels, says Piper Jaffray | | Piper Jaffray believes NuVasive's (NUVA) court hearings are off to a great start with Medtronic's (MDT) injunction being denied. Piper thinks the overhang on NuVasive shares should start to unwind and finds the stock attractive at current levels. The firm reiterates an Overweight rating on the name with a $35 price target. :theflyonthewall.com |
|
| 05:56 EDT | | MDT |
|
|
January 25, 2012
|
| 16:20 EDT |  | MDT |
|
| 15:02 EDT | | MDT |
| theflyonthewall.com: | NuVasive shares spike up on Bloomberg report Medtronic does not get injunction |
 Subscribe for More Information :theflyonthewall.com |
|
| 15:00 EDT | | MDT |
| theflyonthewall.com: | Medtronic tentatively loses bid for injunction against NuVasive, Bloomberg says | | :theflyonthewall.com |
|
| 10:36 EDT | | MDT |
|
|
January 24, 2012
|
| 12:01 EDT | | MDT |
| theflyonthewall.com: | Medtronic completes enrollment in extreme risk study in CoreValve trial | | Medtronic has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The company also received approval from the FDA for an extended investigation to continue enrolling extreme risk patients under a Continued Access Study protocol. In the Trial’s second study evaluating high risk patients for aortic valve surgery, enrollment completion is anticipated later this year. The CoreValve U.S. Trial is evaluating the self-expanding CoreValve System in three sizes and using three delivery access routes: through the transfemoral artery in the upper leg, through the subclavian artery beneath the collar bone, and directly through the aorta via a commonly-used, minimally invasive surgical incision that does not penetrate the heart’s ventricular wall. :theflyonthewall.com |
|
| 09:04 EDT | | MDT |
|
|
January 23, 2012
|
| 09:08 EDT | | MDT |
|
|
January 22, 2012
|
| 15:42 EDT | | MDT |
|
